Observational studyBMC cancer2026
Malignancy in mirror image anatomy reveals situs inversus totalis as an anatomic modifier of oncologic care.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSitus inversus totalis (SIT) is a rare congenital laterality anomaly characterized by complete mirror-image transposition of the thoracic and abdominal viscera. Although SIT is not a proven cancer-predisposition syndrome, cancer in this setting challenges the spatial assumptions that guide diagnosis, staging, surgery, radiotherapy, and surveillance.
methodsWe conducted a retrospective, single-center observational study of patients with radiologically confirmed SIT treated at our cancer center between July 2017 and December 2025. Patients with histologically confirmed malignancy were included. Clinical, pathological, imaging, treatment, and follow-up data were extracted from medical records. Overall survival (OS) was summarized descriptively; Kaplan-Meier analysis was used only to visualize survival and censoring patterns.
resultsAmong 11 patients with SIT, 6 had histologically confirmed malignancies. Median age was 66.5 years (range, 47-76), and median follow-up was 47.5 months (range, 30-55). Tumors included hepatocellular carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, cervical adenocarcinoma, poorly differentiated abdominal adenocarcinoma, and follicular lymphoma transformed to high-grade B-cell lymphoma. Treatment included surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, transarterial chemoembolization, and autologous stem cell transplantation. 4 patients died, and 2 were alive at last contact. Pooled median OS was 50 months and was interpreted only descriptively. Across cases, outcomes reflected tumor type, stage, and molecular features, whereas SIT mainly affected lesion localization, laterality recognition, nodal or vascular mapping, operative orientation, and treatment planning.
conclusionsMalignancy in SIT is best understood as cancer within a reversed anatomical coordinate system. Standard oncologic care remains feasible but requires explicit anatomical verification and multidisciplinary planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.